A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed.

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 698 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 250 sites worldwide.

Sponsor: AbbVie

https://clinicaltrials.gov/ct2/show/record/NCT04928846

• Must have c-Met overexpressing non-small cell lung cancer (NSCLC)
• Have a known epidermal growth factor receptor (EGFR) activating mutation status.
• Have received no more than 1 line of prior systemic cytotoxic chemotherapy 
• No evidence of progression of CNS metastases at least 2 weeks after definitive therapy
• No prior docetaxel therapy
• No history of idiopathic pulmonary fibrosis, organizing pneumonia, or pneumonitis (prior radiation pneumonitis in the radiation field is permitted)